藥物研發市場：按藥物類型、技術和治療領域分類的全球市場預測，2026-2032年

預計到 2025 年，藥物研發市場價值將達到 811.1 億美元，到 2026 年將成長至 925.3 億美元，到 2032 年將達到 2098.7 億美元，複合年成長率為 14.54%。

主要市場統計數據
基準年 2025	811.1億美元
預計年份：2026年	925.3億美元
預測年份 2032	2098.7億美元
複合年成長率 (%)	14.54%

我們將總結推動創新發展的技術促進因素、監管壓力和策略重點，為下一代治療和藥物發現平台奠定基礎。

隨著生物學、工程學和資料科學的融合，從假設到先導化合物的發現途徑不斷拓展，藥物研發格局正以前所未有的速度演變。檢測自動化、計算化學和多組體學分析技術的進步正在縮短藥物研發週期，而監管環境和支付方的期望則要求儘早展現轉換價值。在此背景下，各機構必須應對從試劑採購到後期轉化檢驗等各環節中錯綜複雜的科學機會與營運摩擦。

找出能夠重塑藥物發現工作流程並加速轉化研究成果的變革性科學、技術和經營模式轉變。

多項變革正在重塑藥物研發的營運和策略格局。首先，高內涵資料流與機器學習的整合，使得假設生成和候選化合物篩選能夠以前所未有的規模進行，從而將研究重點從偶然發現轉向資料驅動的先導化合物篩選。其次，實驗流程的模組化，結合自動化和標準化試劑，降低了實驗的變異性，實現了跨地域實驗的可重複性，進而促進了全球合作和快速迭代。

分析美國 2025 年的累積政策和關稅變化及其對供應鏈、採購和製造策略的連鎖反應。

2025年美國實施的政策變化和關稅調整，為藥物研發實驗室廣泛使用的試劑、設備和關鍵組件的採購帶來了新的複雜性。關稅調整影響了進口實驗室設備和某些生化試劑，迫使採購團隊重新評估供應商關係、前置作業時間和總到岸成本。為此，許多機構調整了籌資策略，強調雙重採購、延長合約期限以及與供應商更緊密的合作，以確保獲得優惠配額並減少供應中斷。

識別藥物類型、底層技術和治療領域中以細分市場主導的機會領域，以幫助確定優先順序和投資決策。

從細分市場的觀點來看，不同細分市場在策略、能力投資和夥伴關係設計方面都面臨著不同的挑戰。就藥物類型而言，生物製藥和小分子藥物的研發路徑各不相同，這會影響上游藥物發現的重點和下游的生產決策。生物製藥通常需要對錶達系統和分析表徵進行更深入的投入，而小分子藥物則往往專注於藥物化學、ADMET分析和可擴展的合成途徑。從基礎技術的角度來看，推動生物分析儀器、生物晶片和生物資訊學的平台整合，可以透過實現高解析度資料收集和自動化決策來創造價值。同時，組合化學和高通量篩檢加速了化學多樣性的探索和候選化合物的鑑定。奈米技術和藥物基因體學進一步擴展了標靶遞送和患者分層的工具箱，從而實現更精準的轉化策略。

本研究檢驗了影響全球資源分配、臨床試驗施行地點和製造地。

區域趨勢對組織機構的職能設定、試驗進行地點和組件採購方式有顯著影響。美洲地區創業投資、專業服務供應商和轉化醫學基礎設施高度集中，能夠支持從先導化合物發現到臨床試驗的快速轉化，促進研發團隊與臨床合作夥伴之間的緊密協作。歐洲、中東和非洲（EMEA）地區擁有深厚的科學專長、多元化的法規環境以及對合作研究網路的重視，是開展聯盟計畫和適應性試驗設計的理想區域。亞太地區擁有大規模的生產能力、快速發展的生物技術生態系統以及豐富的臨床研究患者群體，是擴大生產規模和加速患者招募的策略性選擇。

透過對主要企業參與者和創新合作夥伴進行分析，我們將揭示他們在藥物發現生態系統中的競爭地位、夥伴關係趨勢和能力差距。

針對企業和聯盟的分析突顯了能力集中的領域和仍然存在的差距。一些機構透過結合硬體、化學和數據分析的專有平台實現差異化，加速迭代式藥物研發週期並提供獨特的服務模式。另一些機構則透過策略合作拓展業務範圍，建構包含外包研究服務提供者、學術合作夥伴和合約開發組織 (CDO) 的能力組合，從而在不承擔全部固定成本的情況下利用專家知識。此外，一系列技術創新者正在推動檢測靈敏度、小型化和通量的突破，迫使老牌公司重新評估其商業模式和投資重點。

我們提供切實可行的建議，幫助產業領導者調整開發平臺，降低供應鏈風險，並最大限度地發揮新興平台技術的潛力。

產業領導者應謹慎採取措施，使科學研究目標與營運能力相符，同時確保在不確定的環境中擁有多種選擇。首先，透過投資數據標準、模組化自動化和檢驗的分析方法，增強跨平台互通性，確保不同實驗室和使用不同儀器產生的結果具有可比較性和可操作性。其次，減少對單一來源的依賴，並制定包含緊急時應對計畫的採購和供應商發展策略，以因應跨國中斷。第三，透過將臨床導向的檢測、患者來源模型和生物標記開發整合到藥物研發流程中，並優先考慮早期轉化檢驗，降低下游研究的失敗率。

本文檔描述了為整合一手資料和二手資料而採用的嚴謹的混合方法研究途徑，以確保研究結果的可重複性和策略有效性。

這些研究結果所依據的研究採用了混合方法，結合了訪談、技術文獻整合和系統性的能力映射。訪談包括與藥物研發人員、採購經理和監管專家進行結構化對話，以了解營運挑戰和策略重點。二級資訊來源包括同行評審文章、監管指導文件和技術檢驗報告，用於檢驗技術聲明並闡明創新路徑。在資料整合過程中，優先考慮可重複性和可追溯性，將具體觀察結果與資訊來源關聯起來。

我們提供了一個綜合考慮技術、監管和商業性因素的權威視角，為經營團隊決策和策略藍圖。

總之，在當今藥物研發時代，各機構必須兼具科學野心和運作嚴謹性。測量儀器、計算建模和轉化生物學的突破性進展創造了前所未有的機遇，但這些機會也受到價值鏈脆弱性、政策環境不斷變化以及人們對早期臨床意義日益成長的期望等現實因素的影響。那些能夠整合互通平台、制定切實可行的夥伴關係策略並建立健全供應商管理體系的機構，將更有能力將藥物研發成果轉化為臨床進展和商業性價值。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席體驗長觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依藥物類型分類的藥物發現市場

• 生物製藥
• 小分子藥物

第9章 藥物發現市場：依技術分類

• 生物分析儀器
• 生物晶片
• 生物資訊學
• 組合化學
• 高通量篩檢
• 奈米科技
• 藥物基因體學

第10章 藥物研發市場：依治療領域分類

• 心血管疾病
• 消化器官系統疾病
• 感染疾病及免疫系統疾病
• 神經病學
• 腫瘤學

第11章 藥物研發市場：依地區分類

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第12章 藥物研發市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第13章 藥物研發市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第14章：美國藥物研發市場

第15章：中國藥物研發市場

第16章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• Abbott Laboratories
• Agilent Technologies, Inc.
• Alacrita Holdings Limited
• Amgen Inc.
• Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
• Astrazeneca PLC
• Atomwise, Inc.
• BenevolentAI
• Bio-Rad Laboratories, Inc.
• Merck & Co., Inc.

The Drug Discovery Market was valued at USD 81.11 billion in 2025 and is projected to grow to USD 92.53 billion in 2026, with a CAGR of 14.54%, reaching USD 209.87 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 81.11 billion
Estimated Year [2026]	USD 92.53 billion
Forecast Year [2032]	USD 209.87 billion
CAGR (%)	14.54%

Setting the stage for next-generation therapeutics and discovery platforms by summarizing technological drivers, regulatory pressures, and strategic priorities shaping innovation

The drug discovery landscape continues to evolve at an accelerated pace as biology, engineering, and data science converge to create new pathways from hypothesis to lead molecule. Advances in assay automation, computational chemistry, and multiomic analytics are compressing discovery timelines while regulatory frameworks and payer expectations are encouraging earlier demonstration of translational value. Against this backdrop, organizations must navigate a complex interplay of scientific opportunity and operational friction that ranges from reagent sourcing to late-stage translational validation.

In practical terms, this environment rewards disciplined portfolio management and cross-functional collaboration. Translational research groups, external innovation partners, and manufacturing teams must align around clear go/no-go criteria and de-risking milestones so that investment is concentrated on candidates with differentiated biology and plausible development pathways. Moreover, the growing importance of platform technologies and data interoperability means that digital readiness and analytic capability are as strategic as wet-lab prowess. As stakeholders evaluate where to deploy capital and talent, they should consider both near-term feasibility and longer-term platform value so that discovery efforts deliver sustainable competitive advantage.

Identifying the transformative scientific, technological, and business model shifts that are rewriting drug discovery workflows and accelerating translational research outcomes

Several transformative shifts are rewriting the operational and strategic contours of drug discovery. First, the integration of high-content data streams with machine learning is enabling hypothesis generation and candidate triage at scales that were previously impractical, shifting emphasis from serendipitous findings toward data-driven lead selection. Second, modularization of laboratory workflows through automation and standardized reagents reduces variability and enables reproducible experiments across distributed sites, which in turn supports global collaboration and faster iteration.

Third, advances in biologics engineering and small molecule convergence are expanding the addressable biological space, prompting cross-disciplinary teams to rethink target selection and modality strategy. Fourth, regulatory and payer expectations increasingly reward robust translational evidence earlier in development, which places a premium on predictive preclinical models and clinically relevant biomarkers. Finally, strategic partnerships-ranging from technology licensing to co-development alliances-are proliferating as organizations seek to combine complementary capabilities rather than build everything in-house. Together, these shifts demand that organizations adopt flexible operating models, invest in interoperable platforms, and cultivate partnerships that accelerate discovery while managing technical and commercial risk.

Analyzing the cumulative policy and tariff changes in the United States during 2025 and their ripple effects across supply chains, sourcing, and manufacturing strategies

Policy changes and tariff adjustments implemented in the United States during 2025 introduced new layers of complexity for sourcing reagents, instruments, and critical components used across discovery laboratories. Tariff adjustments affected imported laboratory equipment and certain biochemical reagents, prompting procurement teams to reassess supplier relationships, lead times, and total landed costs. In response, many organizations have shifted procurement strategies to emphasize dual sourcing, longer contract horizons, and closer collaboration with suppliers to secure priority allocations and mitigate disruption.

Operationally, elevated import costs led some groups to prioritize onshoring for high-value manufacturing steps or to negotiate volume-based agreements with regional suppliers. Concurrently, research organizations accelerated qualification of alternative reagents and reagents sharing across consortia to preserve experimental continuity. While these adjustments required near-term investment and process redesign, they also catalyzed longer-term supplier development and more robust risk management practices. Moving forward, discovery leaders should continue to monitor policy developments, embed tariff sensitivity into sourcing models, and maintain agile procurement protocols that can respond to sudden changes in cross-border trade conditions.

Uncovering segmentation-driven opportunity zones across drug types, enabling technologies, and therapeutic areas to inform prioritization and investment decisions

Segment-level perspective reveals differentiated implications for strategy, capability investment, and partnership design. When considering drug types, the distinct development pathways for Biologic Drugs versus Small Molecule Drugs shape upstream discovery priorities and downstream manufacturing decisions; biologics typically require deeper investment in expression systems and analytical characterization, while small molecules often emphasize medicinal chemistry, ADMET profiling, and scalable synthetic routes. In terms of enabling technologies, organizations can unlock value by targeting platform integration across Bioanalytical Instruments, Biochips, and Bioinformatics to enable high-resolution data capture and decision automation, while Combinatorial Chemistry and High Throughput Screening accelerate chemical diversity exploration and candidate identification. Nanotechnology and Pharmacogenomics further expand the toolkit for targeted delivery and patient stratification, enabling more precise translational strategies.

Therapeutic area segmentation also directs scientific focus and commercial planning. Oncology and Neurology demand complex translational models and specialized biomarker strategies, whereas Infectious & Immune system Diseases often require rapid-response capabilities and robust pathogen biology expertise. Cardiovascular Disease and Digestive System Diseases call for long-term safety profiling and population stratification considerations. These segmentation lenses together inform where firms should allocate discovery effort, which external partners to engage for specific capabilities, and how to stage investments in in-house platforms versus outsourced services to maximize scientific yield and operational resilience.

Examining regional dynamics and cross-border collaboration patterns that influence resource allocation, clinical trial placement, and manufacturing footprints worldwide

Regional dynamics materially influence where organizations locate capabilities, run trials, and source components. In the Americas, there is strong concentration of venture capital, specialist service providers, and translational infrastructure that supports rapid progression from lead discovery to clinic; this concentration encourages close proximity between discovery teams and clinical collaborators. Europe, Middle East & Africa combines deep scientific expertise, diverse regulatory environments, and an emphasis on collaborative research networks, making it attractive for consortium-based programs and adaptive trial designs. Asia-Pacific presents a mix of high-capacity manufacturing, rapidly growing biotech ecosystems, and a large patient population for clinical research, which makes it a strategic choice for scaling manufacturing and accelerating patient recruitment.

Because regulatory, reimbursement, and operational realities differ across these regions, organizations should design regional strategies that reflect local advantages while maintaining global coherence. This can be achieved by aligning clinical development plans to local regulatory pathways, establishing regional centers of excellence for core capabilities, and orchestrating cross-border data governance that enables reproducible science while meeting jurisdictional compliance requirements. Thoughtful regional allocation of assets and partnerships reduces time-to-insight and enhances the probability that translational findings will survive the transition from lab to clinic.

Profiling leading corporate actors and innovation collaborators to reveal competitive positioning, partnership trends, and capability gaps in discovery ecosystems

A focused view of corporate players and collaborative consortia highlights where capabilities concentrate and where gaps remain. Some organizations distinguish themselves through proprietary platforms that combine hardware, chemistry, and data analytics, enabling them to accelerate iterative discovery cycles and offer differentiated service models. Others pursue breadth through strategic alliances, building capability portfolios that include outsourced research providers, academic partnerships, and contract development organizations to access specialized expertise without bearing full fixed-cost burdens. In addition, a cohort of technology innovators is driving step-change improvements in assay sensitivity, miniaturization, and throughput, which forces incumbents to rethink operational models and investment priorities.

Across the ecosystem, successful actors demonstrate an ability to translate platform capability into translational evidence by integrating rigorous validation pathways and clinical relevance filters. They also manage intellectual property pragmatically, focusing on freedom-to-operate in key geographies while leveraging collaborative licensing to expand development capacity. For organizations assessing competitive positioning, the critical questions are whether to invest in unique platform development, pursue accretive partnerships to fill capability gaps, or adopt a hybrid approach that balances control and flexibility. The optimal path depends on portfolio ambitions, risk tolerance, and the pace at which a given therapeutic area requires clinical validation.

Delivering pragmatic, high-impact recommendations for industry leaders to align R&D pipelines, de-risk supply chains, and capitalize on emergent platform technologies

Industry leaders should take deliberate steps to align scientific ambition with operational capability while preserving optionality in an uncertain environment. First, strengthen platform interoperability by investing in data standards, modular automation, and validated analytics so that results generated in different labs or with different instruments remain comparable and actionable. Second, establish procurement and supplier development strategies that reduce single-source dependencies and incorporate contingency planning for cross-border disruptions. Third, prioritize translational validation early by integrating clinically oriented assays, patient-derived models, and biomarker development into discovery workflows to reduce downstream attrition.

In addition, leaders should cultivate a portfolio approach to externalization: selectively insource core differentiators while outsourcing standardized capabilities to high-quality partners. Complementing these operational moves, invest in talent programs that blend wet-lab expertise, data science, and regulatory insight, and align incentives to reward milestone-driven progress. Finally, pursue pragmatic collaboration models-such as time-limited consortia or milestone-based joint ventures-that enable rapid access to capability without long-term capital overhang. Taken together, these actions will help organizations convert scientific promise into sustainable pipelines and resilient operations.

Explaining the rigorous mixed-method research approach used to synthesize primary and secondary intelligence, ensuring reproducible insights and strategic relevance

The research underpinning these insights employed a mixed-methods approach that combined primary interviews, technical literature synthesis, and systematic capability mapping. Primary engagements included structured conversations with discovery scientists, procurement leaders, and regulatory experts to capture operational pain points and strategic priorities. Secondary sources encompassed peer-reviewed publications, regulatory guidance documents, and technology validation reports to verify technical claims and contextualize innovation trajectories. Data synthesis prioritized reproducibility and traceability, linking specific observations to source material and expert attribution.

To ensure rigor, capability assessments applied consistent evaluation frameworks across technologies and geographies, focusing on maturity, scalability, and translational relevance. Sensitivity analyses explored how variations in supply chain exposure, regulatory pathways, and partnership models could alter operational risk profiles. Throughout, findings were validated through cross-checks with domain experts and iterative review cycles, producing a set of insights designed to be actionable for executives and technical leaders alike.

Drawing conclusive perspectives that integrate technological, regulatory, and commercial factors to inform executive decision-making and strategic roadmaps

In conclusion, the current era of discovery demands that organizations be both scientifically ambitious and operationally disciplined. Breakthroughs in instrumentation, computational modeling, and translational biology create unprecedented opportunity, yet they operate within a reality of supply chain fragility, evolving policy landscapes, and heightened expectations for early clinical relevance. Those who integrate interoperable platforms, pragmatic partnership strategies, and robust supplier management will be better positioned to translate discovery into clinical progress and commercial value.

Moving from insight to impact requires targeted investments in platform integration, talent that spans disciplines, and procurement practices that reduce exposure to single points of failure. By marrying scientific rigor with strategic operational design, leaders can accelerate translational pathways, protect critical workflows from disruption, and sustain long-term innovation. These priorities should inform board-level discussions, R&D planning cycles, and cross-functional initiatives to ensure that discovery efforts remain resilient, focused, and aligned with patient and payer expectations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Market, by Drug Type

• 8.1. Biologic Drugs
• 8.2. Small Molecule Drugs

9. Drug Discovery Market, by Technology

• 9.1. Bioanalytical Instruments
• 9.2. Biochips
• 9.3. Bioinformatics
• 9.4. Combinatorial Chemistry
• 9.5. High Throughput Screening
• 9.6. Nanotechnology
• 9.7. Pharmacogenomics

10. Drug Discovery Market, by Therapeutic Area

• 10.1. Cardiovascular Disease
• 10.2. Digestive System Diseases
• 10.3. Infectious & Immune system Diseases
• 10.4. Neurology
• 10.5. Oncology

11. Drug Discovery Market, by Region

• 11.1. Americas
  • 11.1.1. North America
  • 11.1.2. Latin America
• 11.2. Europe, Middle East & Africa
  • 11.2.1. Europe
  • 11.2.2. Middle East
  • 11.2.3. Africa
• 11.3. Asia-Pacific

12. Drug Discovery Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Drug Discovery Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. United States Drug Discovery Market

15. China Drug Discovery Market

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025
• 16.5. Abbott Laboratories
• 16.6. Agilent Technologies, Inc.
• 16.7. Alacrita Holdings Limited
• 16.8. Amgen Inc.
• 16.9. Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
• 16.10. Astrazeneca PLC
• 16.11. Atomwise, Inc.
• 16.12. BenevolentAI
• 16.13. Bio-Rad Laboratories, Inc.
• 16.14. Merck & Co., Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. UNITED STATES DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 11. CHINA DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. AMERICAS DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 49. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 50. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 51. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 52. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 54. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 55. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 56. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 58. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 59. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 62. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 63. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 64. EUROPE DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 65. EUROPE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 66. EUROPE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 67. EUROPE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 68. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 70. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 71. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 72. AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 74. AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 75. AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 76. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 77. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 78. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 79. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 81. ASEAN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 82. ASEAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 83. ASEAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 84. ASEAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 85. GCC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 86. GCC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 87. GCC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 88. GCC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 89. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 90. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 91. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 92. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 93. BRICS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 94. BRICS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 95. BRICS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 96. BRICS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 97. G7 DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 98. G7 DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 99. G7 DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 100. G7 DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 101. NATO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. NATO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 103. NATO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 104. NATO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. UNITED STATES DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 107. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 108. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 109. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
• TABLE 110. CHINA DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 111. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 112. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 113. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)